Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 19 November 2012 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has unveiled a new amendment to its proposed unique device identification (UDI) rule that would accelerate the implementation schedule of the rule for certain types of medical devices.
The rule has long been under consideration by both FDA and stakeholders. It was required under the 2007 FDA Amendments Act (FDAAA), and was intended to standardize how medical device products are tracked and traced by requiring all devices be marked with an identification number or labeling system.
FDA released a draft version of the UDI rule for consideration on 10 July 2010, but it was held up by the Office of Management and Budget's (OMB) Office of Information and Regulatory Affairs (OIRA) under somewhat mysterious circumstances for well over a year.
On 3 July 2012, FDA released its proposal for the UDI system and a tracking database, known as the Global Unique Device Identification Database (GUDID), which would be used to keep track of all devices' unique identifiers. The system opted for a phased-in approach, with rules coming into effect 1, 3, 5 and 7 years after the publication of the final UDI rule depending on the risk-profile of the device. Riskier devices would be required to comply with the law more quickly, while lower-risk devices would have more time.
Days after the release of the proposed UDI rule, President Barack Obama signed into law the FDA Safety and Innovation Act (FDASIA), a successor bill to FDAAA that renewed user fee bills and called for a number of reforms at FDA.
Among its many requirements, FDASIA requires FDA to release its final UDI rule to the public no later than 31 December 2012. Public comments on a proposed version of the rule were due by 7 November 2012, but FDA may struggle to accommodate the deluge of comments it received on the rule-249 in all. The agency has historically sought to address all comments (though often by condensing them into common complaints) in the final guidance, which is a time-consuming affair.
One notable caveat to the 31 December 2012 requirement: FDA may exempt particular types of devices from the UDI rule. Under FDASIA, certain medical devices-implantable, life-saving, life-supporting or life-sustaining medical devices-will be given two years to comply with Section 519(f), or the UDI rule, of the Federal Food, Drug and Cosmetic Act).
Similarly, all manufacturers will be required to submit identification data to the GUDID within two years of the publication of the final rule.
FDA notes that while this sounds like an extension, the two-year exemption actually accelerates the pace of compliance relative to FDA's original intend. Class III (high risk) implantable medical devices were originally to be granted three years to comply with the rule; Class II devices were to be given five years; Class I (low-risk), seven. Under the new proposal, all will be required to comply in two years.
FDA estimates the total cost of compliance with the rule will now be between $540 million and $608 million based on 2010 dollars.
Tags: UDI Rule, Unique Device Identification, FDASIA, Unique Device Identifier, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.